Protocol Ledger

NCT05429372 · Phase II · TERMINATED

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

Interventional Phase II clinical trial protocol NCT05429372 sponsored by Pfizer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-08 Enrollment: 10 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05429372
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)10 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05429372
Protocol FieldVerified Registry Value
NCT IdentifierNCT05429372
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment10 participants (ACTUAL)
Registered Start Date2022-08-08
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05429372
Hospital Research SiteLocationSite Profile
University of FloridaGainesville, FLOpen Hospital Dossier ->
Children's Hospital of PhiladelphiaPhiladelphia, PAOpen Hospital Dossier ->
Huntsman Cancer Institute at University of UtahSalt Lake City, UTOpen Hospital Dossier ->
Primary Children's HospitalSalt Lake City, UTOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI